All Stories

  1. Anti-tumor effects of a novel cell penetrating peptide-based therapeutic approach to target Lactate Dehydrogenase C (LDHC) in triple negative breast cancer

    Article • March 2025, Cold Spring Harbor Laboratory Press

    Dr Julie Decock

  2. Immunomodulatory effects of tumor Lactate Dehydrogenase C (LDHC) in breast cancer

    Article • December 2024, Cold Spring Harbor Laboratory Press

    Dr Julie Decock

  3. The LDHC-STAT3 Signaling Network Is a Key Regulator of Basal-like Breast Cancer Cell Survival

    Article • Cancers, July 2024, MDPI AG

    Dr Julie Decock

  4. Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer

    Article • Molecular Therapy Oncology, March 2024, Elsevier

    Dr Julie Decock

  5. Untargeted Metabolomic Profiling Reveals Differentially Expressed Serum Metabolites and Pathways in Type 2 Diabetes Patients with and without Cognitive Decline: A Cross-Sectional Study

    Article • International Journal of Molecular Sciences, February 2024, MDPI AG

    Dr Julie Decock

  6. Transcriptome profiling and network enrichment analyses identify subtype-specific therapeutic gene targets for breast cancer and their microRNA regulatory networks

    Article • Cell Death and Disease, July 2023, Springer Science + Business Media

    Dr Julie Decock

  7. Blood-Based Proteomic Profiling Identifies Potential Biomarker Candidates and Pathogenic Pathways in Dementia

    Article • International Journal of Molecular Sciences, May 2023, MDPI AG

    Dr Julie Decock

  8. Blood Proteomics Analysis Reveals Potential Biomarkers and Convergent Dysregulated Pathways in Autism Spectrum Disorder: A Pilot Study

    Article • International Journal of Molecular Sciences, April 2023, MDPI AG

    Dr Julie Decock

  9. Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential

    Article • Journal of Cellular and Molecular Medicine, October 2021, Wiley

    Dr Raham Bacha, Dr Julie Decock

  10. Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy

    Article • Molecular Oncology, June 2021, Wiley

    Dr Julie Decock

  11. Targeting LDHC dysregulates the cell cycle and improves sensitivity to cisplatin and olaparib

    Article • March 2021, Cold Spring Harbor Laboratory Press

    Dr Julie Decock

  12. Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response

    Article • Journal for ImmunoTherapy of Cancer, April 2020, BMJ

    Dr Julie Decock

  13. Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy

    Article • Medical Oncology, January 2020, Springer Science + Business Media

    Dr Julie Decock

  14. Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?

    Article • Cancers, July 2019, MDPI AG

    Dr Julie Decock

  15. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer

    Article • Journal of Translational Medicine, January 2019, Springer Science + Business Media

    Dr Julie Decock

  16. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives

    Article • Frontiers in Immunology, May 2018, Frontiers

    Dr Julie Decock

  17. A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification

    Article • F1000Research, February 2018, Faculty of 1000, Ltd.

    Dr Julie Decock

  18. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications

    Article • International Journal of Molecular Sciences, October 2017, MDPI AG

    Dr Julie Decock

  19. Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function

    Article • March 2017, Springer Science + Business Media

    Dr Julie Decock

  20. A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification

    Article • F1000Research, March 2017, Faculty of 1000, Ltd.

    Dr salha sb Bujassoum Al Bader , Dr Julie Decock, Cristina Maccalli, Jessica Roelands, Ena Wang, Francesco Marincola

  21. Pleiotropic functions of the tumor- and metastasis-suppressing matrix metalloproteinase-8 in mammary cancer in MMTV-PyMT transgenic mice

    Article • March 2015, Springer Science + Business Media

    Dr Julie Decock

  22. Metalloproteinase-dependent and -independent processes contribute to inhibition of breast cancer cell migration, angiogenesis and liver metastasis by a disintegrin and metalloproteinase with thrombospondin motifs-15

    Article • International Journal of Cancer, August 2014, Wiley

    Dr Julie Decock

  23. Matrix metalloproteinases: a dual role in breast cancer?

    Article • Breast Cancer Management, September 2013, Future Medicine

    Dr Julie Decock

  24. Matrix Metalloproteinase 8 (Collagenase 2) Induces the Expression of Interleukins 6 and 8 in Breast Cancer Cells

    Article • Journal of Biological Chemistry, April 2013, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Julie Decock

  25. TGF-β-Elicited Induction of Tissue Inhibitor of Metalloproteinases (TIMP)-3 Expression in Fibroblasts Involves Complex Interplay between Smad3, p38α, and ERK1/2

    Article • PLOS One, February 2013, PLOS

    Dr Julie Decock

  26. Selenium Biomarkers in Prostate Cancer Cell Lines and Influence of Selenium on Invasive Potential of PC3 Cells

    Article • Frontiers in Oncology, January 2013, Frontiers

    Dr Julie Decock

  27. Matrix metalloproteinases: protective roles in cancer

    Article • Journal of Cellular and Molecular Medicine, May 2011, Wiley

    Dr Julie Decock

  28. The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis

    Article • Frontiers in Bioscience, January 2011, Frontiers in Bioscience

    Dr Julie Decock

  29. Short-Term Prognostic Index for Breast Cancer: NPI or Lpi

    Article • Pathology Research International, January 2011, Hindawi Publishing Corporation

    Dr Julie Decock

  30. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors

    Article • Breast Cancer Research and Treatment, July 2008, Springer Science + Business Media

    Dr Julie Decock

  31. Plasma MMP1 and MMP8 expression in breast cancer: Protective role of MMP8 against lymph node metastasis

    Article • BMC Cancer, March 2008, Springer Science + Business Media

    Dr Julie Decock

  32. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive

    Article • Breast Cancer Research and Treatment, February 2008, Springer Science + Business Media

    Dr Julie Decock

  33. Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer

    Article • Clinical Genetics, December 2007, Wiley

    Dr Julie Decock

  34. Association of Matrix Metalloproteinase-8 Gene Variation with Breast Cancer Prognosis

    Article • Cancer Research, November 2007, American Association for Cancer Research (AACR)

    Dr Julie Decock

  35. Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer

    Article • Breast Cancer Research and Treatment, August 2007, Springer Science + Business Media

    Dr Julie Decock

  36. Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers

    Article • Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, June 2007, Elsevier

    Dr Julie Decock

  37. Matrix Metalloproteinase Expression Patterns in Luminal A Type Breast Carcinomas

    Article • Disease Markers, January 2007, Hindawi Publishing Corporation

    Dr Julie Decock

  38. How Accurate Is the Antiprimer Quenching-Based Real-Time PCR for Detection of Her2/neu in Clinical Cancer Samples?

    Article • Clinical Chemistry, July 2006, AACC

    Dr Julie Decock

  39. Proteases and metastasis: clinical relevance nowadays?

    Article • Current Opinion in Oncology, November 2005, Wolters Kluwer Health

    Dr Julie Decock

  40. Plasma Gelatinase Levels in Patients with Primary Breast Cancer in Relation to Axillary Lymph Node Status, Her2/neu Expression and other Clinicopathological Variables

    Article • Clinical & Experimental Metastasis, November 2005, Springer Science + Business Media

    Dr Julie Decock